SILVER SPRING, Md., Jan. 23, 2014 (GLOBE NEWSWIRE) — WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on PharmaCyte Biotech, Inc. (NVLX). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price and the projected fundamental full valuation of $1.90 per share.
Click here to download report:
PharmaCyte Biotech, Inc. (NVLX) is an international biotechnology firm focused on developing and preparing to commercialize treatments for cancer and diabetes built on a proprietary cellulose-based live-cell encapsulation platform, known as Cell-in a-Box(TM), that is therapeutically valuable. PharmaCyte Biotech is leveraging its cancer biology and clinical oncology research experience and expertise, particularly for use in oncology treatments, in addition to initiating the use of the platform in developing oncology applications of medical marijuana.
PharmaCyte Biotech is building a strong foundation in the medical marijuana space with some of the leading experts in the field; this could ultimately position PharmaCyte Biotech to emerge as a leader in the multi-billion dollar marijuana industry. PharmaCyte Biotech’s subsidiary, Medical Marijuana Sciences, Inc., appointed Mark L. Rabe, M.D., Chief Medical Officer (CMO) of California’s largest network of physician-owned medical cannabis evaluation centers, to the position of Chairman of its Scientific Advisory Board. In his position as CMO of the network of cannabis evaluation centers, Dr. Rabe has helped provide over 100,000 medical Cannabis recommendations to patients in 20 different clinics across the state.
In addition, Richard M. Hyslop, Ph.D. has agreed to join the Scientific Advisory Board of Medical Marijuana Sciences. Dr. Hyslop, Professor of Chemistry and Biochemistry at the University of Northern Colorado, has expertise in anti-cancer drug design, the metabolism of anti-cancer drugs and studies of enzymes and enzyme-catalyzed reactions in biological tissues. Dr. Hyslop’s experience with cancer drugs and enzymology will prove to be invaluable in pursuing the goals of Medical Marijuana Sciences that include developing treatments, which employ constituents of Cannabis together with the Cell-in-a-Box(TM) live-cell encapsulation technology, whose rights were acquired by PharmaCyte Biotech in 2013, for some of the deadliest forms of cancer. Dr. Hyslop’s location in the most high profile state in the country related to marijuana use could be a further boon to the Company’s R&D efforts.
WealthMakers is powered by WOPR (WealthMakers Online Predictive Research), http://www.wopronline.com , a military-style computer that uses parallel processing, genetic algorithms, neural networks and unbridled computing power to analyze exactly what event (technicals, fundamentals, earnings, seasonality, short squeeze, group rotation, chart patterns, insider buying/selling and multiple other factors) will move each stock, in which direction, to what % degree, in the specific amount of time and with what degree of probability. Based on IBMs work on Deep Blue (now called “Watson”), this powerful database technology matched with hundreds of data feeds and the ability to find patterns, that humans cannot, has the ability to do the work of hundreds or thousands of analysts without getting tired (24 hours per day / 7 days per week). Our unparalleled technology, trading algorithms and proprietary data generate confident predictions, with clear and concise objectives resulting in unique and innovative research reports that move markets and create exponential returns to our clients.
Wealthmakers Online Predictive Research (WOPR) is a distributed computing system that has hundreds of data feeds (economic, weather, geopolitical, interest rates, energy, equities, currencies, commodities, etc.) feeding into a relational database that searches for patterns and determines how a trading instrument has behaved both before and after specific events have taken place in the past. Only about 25% of stocks display patterns at any given time and only about 1% of stocks exhibit all the necessary conditions on any given day to make a trade. That means that out of 14,000 stocks, only about 140 trades are high probability trades that our system would generate a research report on and disseminate the information to clients. This process eliminates the noise and only tells you which stocks have multiple strategies lining up at the same time, in the same direction, with no conflicting predictions and the fundamental valuation is in-line with the prediction!
EARNINGS – Most stock price histories show random or unpredictable movements around earnings reports. But some repeat the same pattern quarter after quarter, year after year. Earnings predict probability, price move and length of move before and after all US stock earnings reports.
FRICTION FACTOR – Friction Factor is based on the relationship between the price of a stock and the volume at which it’s bought and sold. Normal and abnormal Friction factor patterns can help you time your buying and selling decisions for maximum earnings potential.
GATS – The Global Automated Trading System (GATS) combines neural networks and genetic algorithms to reduce investment risks. GATS selects the highest probability trades in stocks, bonds, options, commodities, currencies and private equities, delivering precise, predictive and profitable data.
GROUP SECTOR – Certain institutions can exert buying or selling pressure over an entire industry group, pushing prices higher. Group Sector identifies stocks that most closely match their group’s movement and generate powerful group consensus trading signals to help you profit from the herd mentality.
PATTERN SCANNER – describes the current technical situation in your stock. It displays the technicals, trend conditions and seasonal factors and automatically discovers how that stock has performed in the trading days following the occurrences of the event or combination of events. This technology automatically scans using complex historical queries based on what event is taking place right now in the stock. It then displays the probability, expected return and number of trading days for the expected move.
EVENTS – This technology automatically tracks “Trigger Events” that positively or negatively affect the value of a stock — or its perceived value among analysts — ranging from price fluctuations to natural disasters and political shifts. The results reveal patterns that can predict market movements.
RegSHO NAKED SHORTS – SEC Regulation SHO mandates that if a clearing agent holds a fail-to-deliver position for 13 consecutive settlement days, it must purchase securities to close out its position, a.k.a. a forced cover. WealthMakers aggregates data from NYSE, AMEX, NASDAQ, OTCBB and PINKSHEETS to track stocks that are about to have forced covers.
SEASONALITY – Seasonality analyzes more than 20 years of data to determine if stocks have a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias.
SQUEEZETRIGGER – Our proprietary database of more than 3,500,000,000 short sale transactions allows us to calculate the exact price at which the total short interest is short in each stock. Squeeze Trigger Alerts let you know exactly when a short squeeze will start and how to trade profitably.
VALUATION – A stock’s value is a function of its forecasted earnings per share and forecasted earnings growth, as well as profitability, interest and inflation rates. Valuation use these metrics to determine at what price a stock is undervalued or overvalued, so that you can make investment decisions accordingly.
INSIDER – Significant stock sales or purchases by company “insiders” (officers or directors) can be a predictor of future price movements, up or down. The Insider strategy tracks these actions and correlates them with historical data to give you an investment edge.
WEALTHMAKERS is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. WEALTHMAKERS has not been compensated by any of the above mentioned companies specifically for this report. Past performance is not indicative of future results. Please visit our web site, www.wealthmakers.com , for complete risks and disclosures.